MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (632)	12/10/2002 2:44:13 AM
From: Icebrg	Read Replies (1) of 2240

Medarex and Genmab Announce Filing of a Clinical Trial Application for MDX-018/HuMax-Inflam Tuesday December 10, 2:30 am ET PRINCETON, N.J. and COPENHAGEN, Denmark, Dec. 10 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) and Genmab A/S (CSE: GEN and FSE: GE9D) today announced the filing of a clinical trial application (CTA) in Europe for MDX- 018, also known as HuMax-Inflam, for use in the treatment of an autoimmune disease. A CTA filing is the equivalent of an investigational new drug (IND) application in the United States and is a request to the regulatory authorities in Europe to seek approval to conduct a clinical study in patients. Medarex and Genmab plan to share all development costs and worldwide rights to MDX-018, except for Asia, which is held by Medarex. The disease and the target mechanism for MDX-018 have not yet been made public.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next